Teva announced that limited doses of the generic version of EpiPen (epinephrine injection, USP) Auto-Injector 0.3mg are now available, following approval from the Food and Drug Administration in August 2018. The generic version of the EpiPen Jr (epinephrine injection, USP) 0.15mg as well as additional supply of the generic version of the EpiPen Auto-Injector 0.3mg will be made available in 2019.
Epinephrine injection, a non-selective alpha and beta-adrenergic receptor agonist, is indicated to treat life-threatening, allergic emergencies including anaphylaxis in patients who are at risk for or have a history of serious allergic emergencies. Its action on alpha-adrenergic receptors reduces the vasodilation and vascular permeability that occurs during anaphylaxis. Its action on beta-adrenergic receptors causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing, and dyspnea that may occur during anaphylaxis.
Teva’s generic EpiPen is available as 0.3mg prefilled auto-injectors in 2-pack cartons; the generic EpiPen Jr will be available as 0.15mg prefilled auto-injectors in 2-pack cartons.
For more information call (888) 838-2872 or visit TevaGenerics.com.
This article originally appeared on MPR